https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
The second class (51% of sample), termed as "UGTI/cost-conscious" were willing to accept significantly lower (6%; CI 2%-11%, and 5%; CI 2%-8%) UGTI risk in exchange for the same reduction in all-cause mortality and hospitalization risks, respectively. On average, patients were willing to trade higher UGTI risk for a more effective medication. Our findings suggest that physicians should present the benefits and potential side effects of all available treatments and consider patient preferences in their treatment recommendati
Like
Comment
Share
